| 张丽.抗骨增生颗粒剂联合常规西药治疗膝骨关节炎的临床研究[J].浙江中西医结合杂志,2024,34(10): |
| 抗骨增生颗粒剂联合常规西药治疗膝骨关节炎的临床研究 |
| Clinical study of anti-osteoproliferative granules assisting conventional Western medicine in the treatment of knee osteoarthritis |
| 投稿时间：2023-12-07 修订日期：2024-08-05 |
| DOI： |
| 中文关键词: 膝骨性关节炎 抗骨增生颗粒剂 临床疗效 炎性因子 |
| 英文关键词:Knee osteoarthritis Anti-bone proliferation granules Clinical effect Inflammatory factor. |
| 基金项目: |
|
| 摘要点击次数: 378 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 探讨抗骨增生颗粒剂联合常规西药治疗膝骨关节炎(KOA)的疗效及安全性。方法 按随机数字表法将我院2020年5月-2023年5月收治的140例KOA患者分入两组(各70例)。对照组给予常规西药治疗,联合组在对照组的基础上联合抗骨增生颗粒剂治疗。对比两组治疗前后中医证候积分、WOMAC膝关节骨关节炎指数、VAS疼痛评分、Lyshom膝关节功能评分和血清C反应蛋白(CRP)等炎性因子水平,分析临床疗效、不良反应。结果 联合组治疗总有效率高于对照组(90.00% vs 77.14%)(χ2=4.214,P=0.040)；治疗后两组患者关节疼痛、腰膝酸软、下肢酸困、牵强不利、身疲乏力、形寒肢冷积分均降低,且联合组上述积分低于对照组(P<0.05)；治疗后两组WOMAC评分中关节疼痛、关节僵硬、关节功能分值均降低,且联合组上述分值低于对照组(P<0.05)；治疗后两组VAS评分均降低,且联合组低于对照组(P<0.05)；治疗后两组Lyshom评分均增高,且联合组高于对照组(P<0.05)；治疗后两组患者CRP、IL-6水平均降低,且联合组上述水平低于对照组(P<0.05)；联合组不良反应率相比对照组差异无统计学意义(2.86% vs 1.43%)(χ2=0.341,P=0.559)。结论 抗骨增生颗粒剂联合常规西药治疗能有效提高KOA患者临床疗效,减轻关节疼痛症状,恢复关节功能,降低机体炎症因子,且安全性较高,值得推广。 |
| 英文摘要: |
| Objective: To explore the effect and safety of anti-osteoproliferative granules assisting conventional Western medicine in the treatment of knee osteoarthritis(KOA). Methods: A total of 140 KOA cases admitted to our hospital from May 2020 to May 2023 were divided into two groups (70 cases each) by random number table. The control group was given with conventional western medicine, and the combination group was given with anti-osteogenic granules on the basis of the control group. TCM syndrome score, WOMAC knee osteoarthritis index, VAS pain score, Lyshom knee function score, serum C-reactive protein (CRP) and other inflammatory factors were compared in two groups, and the clinical efficacy and adverse reactions were analyzed. Results: The total effective rate of the combined group was higher compared with control group (90.00% vs 77.14%) (χ2=4.214, P=0.040). After treatment, the scores of joint pain, waist and knee weakness, lower extremity acid drowsiness, adverse traction, body fatigue, cold shape and cold limb were all decreased in both groups, and the scores in combination group were lower compared with control group(P<0.05). After treatment, the scores of joint pain, joint stiffness and joint function in both groups were decreased, and the above scores in the combined group were lower compared with control group(P<0.05). VAS scores of both groups were decreased after treatment, and the combined group was lower compared with control group(P<0.05). After treatment, the Lyshom score of both groups was increased, and the combined group was higher compared with control group (P<0.05). After treatment, the levels of CRP and IL-6 were decreased in both groups, and the above levels in combination group were lower compared with control group(P<0.05). The adverse reaction rate between the combined group and the control group (2.86%vs1.43%) was no significant difference(χ2=0.341, P=0.559). Conclusion: Anti-osteoproliferative granules combined with conventional western medicine can effectively improve the clinical efficacy of KOA patients, reduce joint pain and other symptoms, restore joint function, reduce the level of inflammatory factors in the body, and have high safety, which is worthy of promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
